Fibrillar protein deposits are characteristic of the affected brain regions of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, as well as many other neurodegenerative diseases. In addition, fibrillar deposits are characteristic of the abnormal pancreatic 13-cells in type II diabetes. The relationship between fibril formation and cell death is unclear, but convergent evidence suggests that fibrillization is causative. It is therefore critical to elucidate the molecular mechanism of fibril formation, so that therapeutic strategies can be devised to stop cell death. This grant is focused on the molecular description of the process whereby a normal soluble protein is converted, through a series of steps, into an insoluble, but ordered amyloid fibril. We have characterized a discrete transient intermediate in the process, designated a protofibril. This species may be the one responsible for disease pathogenesis. However, it is difficult to characterize due to its instability. We will bring to bear several different approaches, from chemical labeling and cross-linking to random mutagenesis, in order to discover a way to stabilize the protofibril intermediate and block its transition to the stable fibrillar state. It is our hope to generate tools, either small molecule inhibitors or inhibitory sequences, that can be used to test the pathogenicity of the protofibril in animal models and will also allow the protofibril to be stabilized and characterized. Finally, we will investigate one possible mechanism by which protofibrils could lead to cell death, that is, inappropriate and uncontrolled membrane permeabilization.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG008470-15
Application #
6629765
Study Section
Special Emphasis Panel (ZRG1-SSS-B (01))
Program Officer
Snyder, Stephen D
Project Start
1989-07-12
Project End
2006-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
15
Fiscal Year
2003
Total Cost
$410,875
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Volles, Michael J; Lansbury Jr, Peter T (2007) Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol 366:1510-22
Fredenburg, Ross A; Rospigliosi, Carla; Meray, Robin K et al. (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46:7107-18
Lashuel, Hilal A; Wall, Joseph S (2005) Molecular electron microscopy approaches to elucidating the mechanisms of protein fibrillogenesis. Methods Mol Biol 299:81-101
Lashuel, Hilal A; Grillo-Bosch, Dolors (2005) In vitro preparation of prefibrillar intermediates of amyloid-beta and alpha-synuclein. Methods Mol Biol 299:19-33
Rochet, Jean-Christophe; Outeiro, Tiago Fleming; Conway, Kelly A et al. (2004) Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 23:23-34
Lashuel, Hilal A; Hartley, Dean M; Petre, Benjamin M et al. (2003) Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 332:795-808
Kheterpal, Indu; Lashuel, Hilal A; Hartley, Dean M et al. (2003) Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry 42:14092-8
Shtilerman, Mark D; Ding, Tomas T; Lansbury Jr, Peter T (2002) Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry 41:3855-60
Anguiano, Magdalena; Nowak, Richard J; Lansbury Jr, Peter T (2002) Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41:11338-43
Volles, M J; Lee, S J; Rochet, J C et al. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-9

Showing the most recent 10 out of 25 publications